PostEra vs Manus AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI medicinal chemistry platform with $1B+ pharma partnerships; $610M Pfizer expansion Jan 2025 ($12M upfront) hitting preclinical milestones 40% faster; $26M raised competing with Schrödinger for AI small molecule and ADC drug design.
About
PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.
General-purpose autonomous AI agent. $125M+ revenue run rate. Acquired by Meta for $2B+ (Dec 2025). Founded 2022, China/Singapore. MIT Innovators Under 35.
About
Manus AI is a general-purpose autonomous AI agent developed by Butterfly Effect Pte Ltd, founded in 2022 by Yichao "Peak" Ji and Xiao Hong. Relocated from China to Singapore (mid-2025). Launched March 6, 2025, autonomously handling complex tasks like market research, coding, data analysis, and content creation without human intervention.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.